Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q1 2020 · 10-Q
Revenue$1.07B$1.07Bno prior Q1 2019 on file Net Income-$596.90K-$596.90KN/M vs Q1 2019 EPS Diluted-$0.08-$0.08N/M vs Q1 2019 Operating Income-$340,050N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Margins · derivedOperating margin-0.0%
Net margin-0.1%
ended Mar 31, 2020 · filed Apr 15, 2021 · 380 d after period end